Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Fineline Cube Apr 30, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

CanSino Biologics’ DTcP Vaccine for Infants and Young Children Accepted by NMPA for Review

Fineline Cube Dec 17, 2024

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) has announced that the National Medical Products...

Company Deals

MicroPort NeuroTech Leads Investment Fund to Advance Brain Science Industry

Fineline Cube Dec 17, 2024

China-based MicroPort NeuroTech Limited (HKG: 2172) has announced its commitment to invest RMB 200 million...

Company Deals

Candid Therapeutics Expands TCE Portfolio with Strategic Partnerships in Autoimmune Disease Treatment

Fineline Cube Dec 17, 2024

US-based Candid Therapeutics Inc. is fulfilling its ambition to become a leader in advancing T-cell...

Company Drug

EMA Grants PRIME Designation to Hansoh Pharmaceutical’s HS-20093 in Collaboration with GSK

Fineline Cube Dec 17, 2024

The European Medicines Agency (EMA) has conferred Priority Medicines (PRIME) designation to HS-20093 (GSK5764227), a...

Company Deals

Bio-Thera Solutions Expands License Deal with SteinCares for Latin American Market

Fineline Cube Dec 17, 2024

China-based Bio-Thera Solutions (SHA: 688177) has announced the addition of a third biosimilar to its...

Company Drug

European CHMP Supports Conditional Approval of MSD’s Welireg for VHL Disease and RCC

Fineline Cube Dec 16, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the European Medicines Agency’s Committee...

Company Drug

EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment

Fineline Cube Dec 16, 2024

Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products...

Policy / Regulatory

Guangdong Province Releases List of Urgent Clinical Drugs and Devices for GBA Cities

Fineline Cube Dec 16, 2024

The medical products administration and health commission of Guangdong province have released a list of...

Company Drug

Sanofi’s Tolebrutinib Earns FDA Breakthrough Designation for Non-Relapsing Secondary Progressive MS

Fineline Cube Dec 16, 2024

Sanofi (NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA) has granted...

Company Medical Device

Roche’s cobas 6800/8800 Systems 2.0 Earn CE Certification, Set for US Market Entry

Fineline Cube Dec 16, 2024

Global healthcare company Roche (SWX: ROG) has announced that its state-of-the-art cobas 6800/8800 Systems 2.0...

Company Drug

ARS Pharmaceuticals’ Neffy Receives Market Filings in Asia-Pacific Region

Fineline Cube Dec 16, 2024

US-based ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has announced that market filings for its intranasal epinephrine...

Company Drug

Fujian Cosunter Pharmaceutical’s GST-HG141 Earns Breakthrough Designation for Chronic Hepatitis B

Fineline Cube Dec 16, 2024

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Beijing Conference Outlines 2025 Healthcare Security Goals and 2024 Progress

Fineline Cube Dec 16, 2024

A national conference on healthcare security was recently held in Beijing, reviewing the achievements of...

Company Deals

Quantum Hi-Tech (ChemPartner) Plans to Raise Over RMB 930 Million in Private Placement

Fineline Cube Dec 16, 2024

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), is poised to raise...

Company Deals

AbbVie Acquires Roche’s Nimble Therapeutics to Boost Immunology Pipeline

Fineline Cube Dec 16, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has reached an agreement to acquire Swiss pharmaceutical giant...

Company Deals

iFlytek’s Xunfei Healthcare Passes HKEX Hearing for AI-Powered Medical IPO

Fineline Cube Dec 16, 2024

Xunfei Healthcare Technology Co., Ltd., a subsidiary of China’s leading information technology company iFlytek Co.,...

Company Deals

Innovent Biologics Partners with Eli Lilly for Distribution of Jaypirca in China

Fineline Cube Dec 16, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has entered into a significant distribution and promotion agreement...

Company Drug

Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101

Fineline Cube Dec 16, 2024

Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China,...

Company Drug

EMA’s CHMP Supports Approval of Eli Lilly’s Omvoh (Mirikizumab) for Crohn’s Disease

Fineline Cube Dec 16, 2024

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...

Company Drug

Wepon Medical’s WP107 for Myasthenia Gravis Accepted for FDA Review

Fineline Cube Dec 16, 2024

Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced that the US Food and...

Posts pagination

1 … 239 240 241 … 660

Recent updates

  • Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC
  • GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength
  • GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership
  • AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength
  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Company

GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength

Company

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

Others

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.